A Banner Year for Biosimilars: The 19 FDA Approvals From 2024

Biosimilars Drive Cost Savings and Achieve 53% Market Share Across Treatment Areas

January 16th 2025

By Skylar Jeremias

Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar competition, according to Samsung Bioepis’ most recent market report, showcasing notable pricing trends and market share disparities across therapeutic areas.

Biosimilar Tocilizumab Cost-Effective for Treatment of Rheumatoid Arthritis in Spain

January 16th 2025

By Cameron Santoro

A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid arthritis (RA) after experiencing improved outcomes.

Improving Biosimilar Access Through Global Regulatory Convergence

January 15th 2025

By Skylar Jeremias

Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access, reducing costs, and enhancing patient outcomes by streamlining approval processes, fostering international collaboration, and addressing regulatory disparities.

Cost-Efficiency in Action: Denmark's Transition to Biosimilar Adalimumab

January 14th 2025

By Skylar Jeremias

The nationwide mandatory switch from Humira (reference adalimumab) to biosimilar adalimumab in Denmark led to no increase in total health care costs over 9 months, with significant cost reductions for those who switched to GP2017 specifically, highlighting the economic feasibility of biosimilar adoption.

The Next Frontier: Oncology Biosimilars in 2025 and Beyond

January 13th 2025

By Prateek Yadav, MPTh, MBA

The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.

Streamlining Biosimilar Access: How EHR Automation Transforms Patient Care

January 12th 2025

By Skylar Jeremias

Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals

January 11th 2025

By Skylar Jeremias

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.

The Top 5 Biosimilar Articles for the Week of January 6

January 10th 2025

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of January 6, 2025.

Earlier Patent Litigation Could Accelerate US Biosimilar Market Entry

January 9th 2025

By Cameron Santoro

Reforming patent litigation to mirror successful outcomes across Europe could significantly accelerate US biosimilar market entry.

Equivalence Confirmed: CT-P41 Paves the Way for Affordable Osteoporosis Care

January 8th 2025

By Skylar Jeremias

Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in a phase 3 trial involving postmenopausal women with osteoporosis, paving the way for improved accessibility and cost savings in osteoporosis treatment.